GE Healthcare has received Food and Drug Administration 510(k) approval of new diagnostic imaging technology for breast care.

The SenoBright Contrast Enhanced Spectral Mammography technology uses a dye with iodine and a "dual energy acquisition technique" to provide contrast-enhanced images of the breast. SenoBright uses X-rays at multiple energies to create two separate but almost simultaneous exposures, according to the Waukesha, Wis.-based vendor.

The result is two images per mammographic view, one looking like a standard mammography and the other showing contrast-enhanced areas that can help localize a lesion, particularly near dense breast tissue.

GE Healthcare estimates about 2,500 digital mammography systems are upgradeable to SenoBright. More information is available here.


Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access